Exhibit 99.1 OPKO Health Reports Second Quarter 2024 Business Highlights and Financial Results Conference call begins at 4:30 p.m. Eastern time today MIAMI (August 7, 2024) – OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and six months ended June 30, 2024. Highlights from the second quarter and recent weeks include the following: ● Enrollment underway in the MDX2001 Phase 1 trial for the treatment of solid tumor cancers. MDX2001, a tetraspecific antibody, is ...

MIAMI, July 18, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) today announced that its Board of Directors has authorized the repurchase of up to $100 million of shares of the Company's common stock. Under the repurchase program, OPKO may repurchase shares of its common stock from time to time through open market purchases, block trades, privately negotiated transactions, accelerated share repurchase transactions and/or pursuant to Rule 10b5-1 plans, in compliance with applicable securities laws an ...

MIAMI, July 17, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) announces it has entered into a $250 million non-dilutive note purchase agreement with HealthCare Royalty (HCRx) secured by OPKO's profit share payments from Pfizer received pursuant to its license agreement relating to NGENLA™, a once-weekly treatment currently marketed to treat pediatric growth hormone deficiency. "This transaction with HCRx allows OPKO to retain a significant portion of NGENLA's profit share payments in the near ter ...

It has been about a month since the last earnings report for OPKO Health (OPK) . Shares have added about 12.8% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is OPKO Health due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers. OPKO Health's Q1 Earnings Miss Estimates, Sale ...

OPKO is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development, and commercialization expertise and novel and proprietary technologies. For more information, visit www.opko.com. Contacts: LHA Investor Relations Yvonne Briggs, 310-691-7100 ybriggs@lhai.com or Bruce Voss, 310-691-7100 bvoss@lhai.com MIAMI, May 31, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) announced tod ...

OPKO Health, Inc. (OPK) delivered a loss per share of 12 cents in the first quarter of 2024, wider than the year-ago period’s loss of 2 cents per share. The figure missed the Zacks Consensus Estimate of a loss of 9 cents per share by 33.3%.Revenues in DetailOPKO Health registered sales of $173.7 million, down 26.9% year over year. The figure missed the Zacks Consensus Estimate by 5%.Lower revenues from the transfer of intellectual property and others dragged the overall top line.Segmental RevenuesOPKO Healt ...

For the quarter ended March 2024, OPKO Health (OPK) reported revenue of $173.7 million, down 26.9% over the same period last year. EPS came in at -$0.12, compared to -$0.02 in the year-ago quarter.The reported revenue represents a surprise of -5.00% over the Zacks Consensus Estimate of $182.84 million. With the consensus EPS estimate being -$0.09, the EPS surprise was -33.33%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Stre ...

Start Time: 16:30 January 1, 0000 5:21 PM ET OPKO Health, Inc. (NASDAQ:OPK) Q1 2024 Earnings Conference Call May 07, 2024, 16:30 PM ET Company Participants Phil Frost - Chairman and CEO Elias Zerhouni - President and Vice Chairman Adam Logal - SVP and CFO Charles Bishop - CEO, OPKO Renal Gary Nabel - Chief Innovation Officer Yvonne Briggs - LHA IR Conference Call Participants Maury Raycroft - Jefferies Jeff Cohen - Ladenburg Thalmann Company Edward Tenthoff - Piper Sandler Yale Jen - Laidlaw & Company Yi Ch ...

OPKO Health (OPK) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.02 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -33.33%. A quarter ago, it was expected that this holding company with investments in pharmaceutical and diagnostics companies would post a loss of $0.09 per share when it actually produced a loss of $0.09, delivering no surpri ...

Financial Performance - Total revenues for the three months ended March 31, 2024, were $173.7 million, a decrease of 27% compared to $237.6 million for the same period in 2023[239] - The company recorded a consolidated loss from operations of $71.5 million for the three months ended March 31, 2024, compared to a loss of $30.6 million for the same period in 2023, representing a 134% increase in loss[239] - Total revenues for the three months ended March 31, 2024, were $46.8 million, a decrease of $58.4 million or 55.5% compared to $105.2 million in the same period of 2023[246] Revenue Breakdown - Revenue from services decreased by approximately $5.5 million, or 4.1%, primarily due to lower clinical test volume and reduced test reimbursement[240] - Revenue from products decreased by $2.3 million or 5.8% to $38.0 million, primarily due to declining international sales and foreign exchange fluctuations[247] - Revenue from the transfer of intellectual property and other dropped by $56.1 million or 86.5% to $8.7 million, largely due to one-time milestone payments received in 2023[248] Expenses - The cost of revenue for the three months ended March 31, 2024, decreased by $4.2 million, or 3.7%, compared to the same period in 2023[242] - Selling, general and administrative expenses decreased by 13% to $45.8 million for the three months ended March 31, 2024, down from $52.6 million in 2023[243] - Research and development expenses for the three months ended March 31, 2024, totaled $0.7 million, a decrease of 3.5% compared to $0.7 million in 2023[244] - Research and development expenses decreased by $10.6 million or 33.3% to $21.2 million, influenced by a one-time payment to Sanofi in 2023[251] - Selling, general and administrative expenses increased by $1.5 million or 11% to $15.0 million, driven by higher employee-related and professional expenses[250] Financing Activities - The company completed a private offering of $230 million aggregate principal amount of 3.75% Convertible Senior Notes due 2029, with net proceeds of approximately $222 million[232] - The company entered into a definitive agreement to sell select assets of BioReference for $237.5 million, expected to close in the second half of 2024[229] - The company completed a private offering of $230.0 million aggregate principal amount of 2029 Convertible Notes in January 2024[265] Cash and Liquidity - The company had cash and cash equivalents of approximately $75.6 million as of March 31, 2024, with cash used in operations amounting to $35.5 million[263] - Cash and cash equivalents on hand as of March 31, 2024, are deemed sufficient to meet anticipated cash requirements for operations and debt service beyond the next 12 months[277] Regulatory and Development Updates - The company anticipates regulatory approvals for Somatrogon (hGH-CTP) in over 50 markets, expanding its pharmaceutical pipeline[226] - ModeX was awarded a BARDA Contract for $59.0 million over five years to develop a next-generation MSTAR multispecific antibody against SARS-CoV-2, with potential additional funding of up to $109.6 million upon achieving milestones[270] - The company incurred $10.8 million in development costs related to the Epstein-Barr Virus vaccine, fully reimbursed by Merck[272] Currency and Interest Rate Management - Approximately 21.5% of the company's revenue for the three months ended March 31, 2024, was denominated in currencies other than the U.S. Dollar, up from 18.5% in the same period in 2023[236] - The company manages foreign currency exchange rate risk by entering into foreign exchange forward contracts to hedge forecasted cash flows[287] - The company does not hedge interest rate exposure due to the short-term nature of its investment portfolio, which is subject to minimal interest rate risk[289] Commitments and Obligations - As of March 31, 2024, total commitments under the amended credit agreement were $40.6 million, with $21.0 million drawn and a weighted average interest rate of approximately 7.8%[274] - As of March 31, 2024, the total contractual obligations amounted to $499.3 million, with $60.7 million due in the remaining nine months of 2024[279]